LOXO ONCOLOGY, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.loxooncology.com
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT06588478
- Locations
- πΊπΈ
Ironwood Cancer & Research Centers, Chandler, Arizona, United States
πΊπΈCity of Hope National Medical Center, Irvine, California, United States
πΊπΈPalo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto, California, United States
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple SclerosisMultiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT06104683
- Locations
- πΊπΈ
Clinical Trial Network, Houston, Texas, United States
πΊπΈSwedish Medical Center-501 E Hampden Ave, Seattle, Washington, United States
π΅π·Caribbean Center For Clinical Research Inc, Guaynabo, Puerto Rico
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05324124
- Locations
- πΈπ¬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaLeukemia, B-cellLeukemia, LymphocyticSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT05254743
- Locations
- πΊπΈ
Eisenhower Army Medical Center, Rancho Mirage, California, United States
πΊπΈAlta Bates Summit Medical Center, Berkeley, California, United States
πΊπΈBaylor Scott & White Health, Round Rock, Texas, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05176314
- Locations
- πΊπΈ
Covance Dallas, Dallas, Texas, United States
πΊπΈQPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Lymphocytic, SmallLymphoma, Mantle-CellWaldenstrom MacroglobulinemiaRitcher's Transformation, Syndrome
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT05172700
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05136404
- Locations
- πΊπΈ
LabCorp CRU, Inc., Daytona Beach, Florida, United States
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05134337
- Locations
- πΊπΈ
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05134350
- Locations
- πΊπΈ
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT05089019
- Locations
- πΊπΈ
LabCorp CRU, Inc., Madison, Wisconsin, United States
πΊπΈCovance Dallas, Dallas, Texas, United States
πΊπΈAnaheim Clinical Trials, LLC, Anaheim, California, United States